Final Report Summary - TMAC (TARGETING TUMOUR ASSOCIATED MACROPHAGES IN CANCER)
These studies have established that IKKb/NF-kB signalling in tumour-associated myeloid cells contributes to immune suppression and promotes tumour growth, this suggests IKKb could be an important immune-checkpoint that can be targeted for immunotherapy in cancer. Based on these studies efforts are ongoing to develop strategies to target IKKb inhibitors specifically to myeloid cells in tumours as a novel immune-checkpoint therapy, we hope hope these further studies will lead to new therapeutic approaches for cancer.